Skip to main content

Advertisement

SpringerLink
Log in

Bone markers in osteoporosis

  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Current biological markers of bone turnover have proven useful in improving fracture risk assessment and monitoring treatment efficacy in postmenopausal osteoporosis. Recent developments in the field of bone markers include 1) identification of new biochemical markers providing additional information on the complex pathways leading to bone fragility; 2) application of novel technologies such as proteomics for the discovery of novel markers; 3) automation and multiplexing for improving analytical performance and convenience; and 4) refinement of the clinical interpretation of markers. Currently, however, for the management of individual patients, their most established application is to monitor treatment efficacy and possibly to improve fracture risk assessment. The role of bone markers for improving adherence to therapy will need to be investigated in further studies. This brief review discusses these novel technological developments and the recent clinical data on the use of established and new markers in postmenopausal osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Garnero P, Delmas PD: Investigation of bone: biochemical markers. In Rheumatology, 4rd edn. Edited by Hochberg MC, Silman AJ, Smolen JS, et al.: London: Harcourt Health Sciences Ltd.; 2007:1943–1953.

    Google Scholar 

  2. Szulc P, Delmas PD. Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis Int 2008, 19:1683–1704.

    Article  CAS  Google Scholar 

  3. Cremers S, Garnero P: Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 2006, 66:2031–2058.

    Article  PubMed  CAS  Google Scholar 

  4. Garnero P: New biochemical markers of bone turnover. IBMS BoneKEy 2008, 5:84–102.

    Article  Google Scholar 

  5. Srivastava AK, Mohan FR, Singer FR, et al.: A urine midmolecule osteocalcin assay shows higher discriminatory power than a serum midmolecule osteocalcin assay during short-term alendronate treatment of osteoporotic patients. Bone 2002, 31:62–69.

    Article  PubMed  CAS  Google Scholar 

  6. Fedarko NS, Jain A, Karadag A, et al.: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7:4060–4066.

    PubMed  CAS  Google Scholar 

  7. Kudo Y, Siriwardena BS, Hatano H, et al.: Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007, 22:1167–1174.

    PubMed  CAS  Google Scholar 

  8. Lenora J, Ivaska KK, Obrant KJ, et al.: Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007, 18:1297–1305.

    Article  PubMed  CAS  Google Scholar 

  9. Gerdhem P, Ivaska KK, Alatalo SL, et al.: Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004, 19:386–393.

    Article  PubMed  CAS  Google Scholar 

  10. Sasaki H, Yu CY, Dai M, et al.: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003, 77:245–252.

    Article  PubMed  CAS  Google Scholar 

  11. Halleen JM, Alatalo SL, Suominen H, et al.: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000, 15:1337–1345.

    Article  PubMed  CAS  Google Scholar 

  12. Hannon RA, Clowes JA, Eagleton AC, et al.: Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004, 34:187–194.

    Article  PubMed  CAS  Google Scholar 

  13. Kearns AE, Khosla S, Kostenuik P: RANKL and OPG regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155–192.

    Article  PubMed  CAS  Google Scholar 

  14. Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005, 90:6323–6331.

    Article  PubMed  CAS  Google Scholar 

  15. Day TF, Guo X, Garrett-Beal L, et al.: Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005, 8:739–750.

    Article  PubMed  CAS  Google Scholar 

  16. Voorzanger-Rousselot N, Journe F, Doriath V, et al.: Assessment of circulating Dickkopf-1 with a new two site immunoassay in healthy subjects and women with breast cancer and bone metastases. Calcif Tissue Int 2009, 84:348–354.

    Article  PubMed  CAS  Google Scholar 

  17. Tian E, Zhan F, Walker R, et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483–2494.

    Article  PubMed  CAS  Google Scholar 

  18. Voorzanger-Rousselot N, Goehrig D, Journe F, et al.: Increased dickkopf-1 (Dkk-1) expression in breast cancer bone metastases. Br J Cancer 2007, 97:964–970.

    PubMed  CAS  Google Scholar 

  19. Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156–163.

    Article  PubMed  CAS  Google Scholar 

  20. Lane NE, Nevitt MC, Lui LY, et al.: Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women. Arthritis Rheum 2007, 56:3319–3325.

    Article  PubMed  CAS  Google Scholar 

  21. Voorzanger-Rousselot N, Goehrig D, Facon T, et al.: Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol. 2009, 145:264–266.

    Article  PubMed  CAS  Google Scholar 

  22. Leeming DJ, Henriksen K, Byrjalsen I, et al.: Is bone quality associated with bone remodeling. Osteoporos Int 2009, Mar 28 (Epub ahead of print).

  23. Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013–1019.

    Article  PubMed  CAS  Google Scholar 

  24. Schwartz AV, Garnero P, Hillier AT, et al.: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, Apr 21 (Epub ahead of print).

  25. Garnero P, Gineyts E, Schaffer AV, et al.: Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s Disease. Arthritis Rheum 1998, 41:354–360.

    Article  PubMed  CAS  Google Scholar 

  26. Alexandersen P, Peris P, Guanabens N, et al.: Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget’s disease of bone. J Bone Miner Res 2005, 20:588–595.

    Article  PubMed  CAS  Google Scholar 

  27. Leeming DJ, Hegele A, Byrjalsen I, et al.: Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers. Cancer Epidemiol Biomarkers Prev 2008, 17:1269–1276.

    Article  PubMed  CAS  Google Scholar 

  28. Garnero P, Schott AM, Prockop D, Chevrel G: Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations. Bone 2009, 44:461–466.

    Article  PubMed  CAS  Google Scholar 

  29. Garnero P, Cloos P, Sornay-Rendu E, et al.: Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res 2002, 17:826–833.

    Article  PubMed  CAS  Google Scholar 

  30. Byrjalsen I, Leeming DJ, Qvist P, et al.: Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int 2008, 19:339–348.

    Article  PubMed  CAS  Google Scholar 

  31. Karsdal MA, Byrjalsen I, Leeming DJ, et al.: The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality. Osteoporos Int 2008, 19:1355–1361.

    Article  PubMed  CAS  Google Scholar 

  32. Garnero P, Bauer DC, Mareau E, et al.: Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study. J Bone Miner Res 2008, 23:1442–1448.

    Article  PubMed  CAS  Google Scholar 

  33. Garnero P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum assay for total N terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54:188–196.

    Article  PubMed  CAS  Google Scholar 

  34. Bhattacharyya S, Siegel ER, Achenbach SJ, et al.: Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res 2008, 23:1106–1117.

    Article  PubMed  CAS  Google Scholar 

  35. Claudon A, Vergnaud P, Valverde C, et al.: A new automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 2008, 54:1554–1563.

    Article  PubMed  CAS  Google Scholar 

  36. Kanis JA, McCloskey EV, Johansson H, et al.: Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395–1408.

    Article  PubMed  CAS  Google Scholar 

  37. Stepan JJ: Prediction of bone loss in postmenopausal women Osteoporos Int 2000, 11(Suppl 6):S45–S54.

    Article  PubMed  Google Scholar 

  38. Ivaska KK, Lenora J, Gerdhem P, et al.: Serial assessment of serum bone metabolism markers identifies women with highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab 2008, 93:2622–2632.

    Article  PubMed  CAS  Google Scholar 

  39. Garnero P, Delmas PD: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskel Neuron Interact 2004, 4:50–63.

    CAS  Google Scholar 

  40. Johnell O, Oden A, De Laet C, et al.: Biochemical markers and the assessment of fracture probability. Osteoporos Int 2002, 13:523–526.

    Article  PubMed  CAS  Google Scholar 

  41. Sornay-Rendu E, Munoz F, Garnero P, et al.: The identification of osteopenic women at high risk of fracture: The OFELY study. J Bone Miner Res 2005, 20:1813–1819.

    Article  PubMed  Google Scholar 

  42. Seibel MJ, Naganathan V, Barton I, Grauer A:. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004, 19:323–329.

    Article  PubMed  CAS  Google Scholar 

  43. Bauer DC, Garnero P, Hochberg MC, et al.: Pre-treatment bone turnover and fracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 2006, 21:292–299.

    Article  PubMed  CAS  Google Scholar 

  44. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962–970.

    Article  PubMed  CAS  Google Scholar 

  45. Bauer DC, Garnero P, Bilezikian JP, et al.: Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006, 91:1370–1375.

    Article  PubMed  CAS  Google Scholar 

  46. Delmas PD, Licata AA, Reginster JY, et al.: Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006, 39:237–243.

    Article  PubMed  CAS  Google Scholar 

  47. Seeman E: Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 2007, 4:308–317.

    Article  Google Scholar 

  48. Sarkar S, Reginster JY, Crans GG, et al.: Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004, 19:394–401.

    Article  PubMed  Google Scholar 

  49. Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051–1056.

    Article  PubMed  CAS  Google Scholar 

  50. Eastell R, Hannon RA, Garnero P, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 2007, 22:1656–1660.

    Article  PubMed  Google Scholar 

  51. Bauer DC, Black DM, Garnero P, et al.: Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004, 19:1250–1258.

    Article  PubMed  Google Scholar 

  52. Delmas PD, Munoz F, Cosman F, et al.: Relationship of bone turnover marker (PINP) and changes in femoral neck bone mineral density to fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg (ZOL): the Horizon-PFT study [abstract]. J Bone Miner Res 2008, 23:S9.

    Google Scholar 

  53. Glover SJ, Garnero P, Naylor K, et al.: Establishing a reference range for bone turnover markers in young, healthy women. Bone 2008, 42:623–630.

    Article  PubMed  CAS  Google Scholar 

  54. Glover S, Gall M, Schoenborn-Kellenberger O, et al.: Establishing a reference interval for bone Turnover markers in 637 healthy, young, pre-menopausal women from UK, France, Belgium and the USA. J Bone Miner Res 2009, 24:389–397.

    Article  PubMed  Google Scholar 

  55. Clowes JA, Peel NF, Eastell R: The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:1117–1123.

    Article  PubMed  CAS  Google Scholar 

  56. Delmas PD, Vrijens B, Eastell R, et al.: Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007, 4:1296–1304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Synarc, 16 rue Montbrillant, 69003, Lyon, France

    Patrick Garnero

Authors
  1. Patrick Garnero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Garnero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garnero, P. Bone markers in osteoporosis. Curr Osteoporos Rep 7, 84–90 (2009). https://doi.org/10.1007/s11914-009-0014-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-009-0014-3

Keywords

Search

Navigation